Mesenchymoma

A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)

Also Known As:

Networked: 17 relevant articles (0 outcomes, 2 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Sarcoma (Soft Tissue Sarcoma)
3.	Neuroblastoma
4.	Hepatocellular Carcinoma (Hepatoma)
5.	Disease Progression

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mesenchymoma:

1.	Carbon MonoxideIBA 01/01/1975 - " The article discusses merits of the classification, its importance in unification of the nomenclature on bone tumours, in studies of their nature and histogenesis, etc. At the same time some drawbacks of the classification are noted: lack of accuracy with respect to the nomenclature and grouping of the so-called giant-cell tumours of bones, with respect to the group of tumours of the "bone marrow", the group of mesenchymomas, etc. The author makes his critical notes on the basis of the experience gained by his co-workers and by himself."
2.	HormonesIBA 09/02/1961 - "[New insight into hormone-producing mesenchymomas of the ovary]." 09/01/1961 - "[New insights into hormone-producing mesenchymomas of the ovary]." 12/01/1960 - "New views on the hormone-producing mesenchymomas of the ovaries."
3.	Malignant mesenchymal tumorIBA 10/01/1984 - "The histology was hepatoblastoma in 39 patients, hepatocellular carcinoma in 4, fibrolamellar carcinoma in 4, and malignant mesenchymal tumor (mesenchymoma) in 1. The patients with hepatocellular carcinoma and mesenchymoma all died. " 07/01/1993 - "The differential diagnosis for these extraskeletal osseous and cartilaginous lesions includes soft-tissue sarcoma, benign mesenchymoma, malignant mesenchymoma (rare), calcified tophi in gout, melorheostosis (rare), pilomatricoma (rare), and tumoral calcinosis (rare)."
4.	Gonadal Steroid Hormones (Sex Hormones)IBA 06/01/1999 - "We differentiate two groups: 1. Feminizing mesenchymomas, which secrete female sex hormones and 2. Virilizing tumors, which secrete male sex hormones. "
5.	Phenytoin (Dilantin)FDA LinkGeneric 05/01/1985 - "The possibility of transplacental carcinogenesis should be considered, as other juvenile embryonic tumors such as neuroblastoma, melanotic neuroectodermal tumor, and mesenchymoma have been reported in offspring after diphenylhydantoin use by the mother during pregnancy."
6.	MethylcholanthreneIBA 07/01/1955 - "[Decrease in malignancy of methylcholanthrene-induced tumors (mesenchymomas) in white rats following thymus extract therapy]."
7.	FibrinIBA 12/01/1975 - "Thirty-two children with solid tumors (lymphangioma, fibrosarcoma, hepatocarcinoma, osteogenic sarcoma, rhabdomyosarcoma, lymphosarcoma, mesenchymoma, hepatoma, Ewing's sarcoma, reticulum cell sarcoma, neuroblastoma, Hodgkin's disease, and brain tumors) were studied for alterations in coagulation by means of platelet counts, platelet aggregation, thrombelastogram, procoagulant and antigenic factor VIII, fibrin split products, and antithrombin III level. "
8.	Factor VIII (Coagulation Factor VIII)IBA 12/01/1975 - "Thirty-two children with solid tumors (lymphangioma, fibrosarcoma, hepatocarcinoma, osteogenic sarcoma, rhabdomyosarcoma, lymphosarcoma, mesenchymoma, hepatoma, Ewing's sarcoma, reticulum cell sarcoma, neuroblastoma, Hodgkin's disease, and brain tumors) were studied for alterations in coagulation by means of platelet counts, platelet aggregation, thrombelastogram, procoagulant and antigenic factor VIII, fibrin split products, and antithrombin III level. "
9.	Antithrombin IIIIBA 12/01/1975 - "Thirty-two children with solid tumors (lymphangioma, fibrosarcoma, hepatocarcinoma, osteogenic sarcoma, rhabdomyosarcoma, lymphosarcoma, mesenchymoma, hepatoma, Ewing's sarcoma, reticulum cell sarcoma, neuroblastoma, Hodgkin's disease, and brain tumors) were studied for alterations in coagulation by means of platelet counts, platelet aggregation, thrombelastogram, procoagulant and antigenic factor VIII, fibrin split products, and antithrombin III level. "
10.	AntibodiesIBA 01/01/1996 - "Further immuno-transmission-electron microscopical investigations with intermediate filament or macrophage antibodies are needed to clarify whether the term malignant "fibrohistiocytic sarcoma", "mesenchymoma" or "mesothelioblastoma" would be more correct from the morphological point of view."

Therapies and Procedures

1.	Transplantation (Transplant Recipients) 01/01/1971 - "XI. Appearance of malignant mesenchymomas during successive transplantation trials]."
2.	Drug Therapy (Chemotherapy) 01/01/1988 - "Childhood hepatic mesenchymoma: successful treatment with surgery and multiple-agent chemotherapy." 08/01/1989 - "Two children who had incomplete resection with microscopic residual mesenchymoma both had tumor recurrence and died of disease progression despite radiation therapy and chemotherapy. "
3.	Adjuvant Chemotherapy 01/01/1988 - "In this report, two children with hepatic mesenchymoma underwent surgical excision followed by 2 years of adjuvant chemotherapy. "
4.	Traction 01/01/1997 - "In this report we describe a benign mesenchymoma of the mediastinum which presented itself with symptoms and signs of the traction diverticula of the esophagus."